This article has been cited by
1Treatment of membranous nephropathy: time for a paradigm shift
Piero Ruggenenti,Fernando C. Fervenza,Giuseppe Remuzzi
Nature Reviews Nephrology.2017;13(9)563
2MicroRNAs in the key events of systemic lupus erythematosus pathogenesis
Marketa Husakova
Biomedical Papers.2016;160(3)327
3Systemic lupus erythematous exacerbation following cessation of belimumab treatment: comments on the article by Furer et al
S Carbajal1,C Zamora-Martínez,S Prieto-González,LF Quintana,G Espinosa1,R Cervera
Scandinavian Journal of Rheumatology.2017;46(3)250
4NF-?B in inflammation and renal diseases
Haisong Zhang,Shao-Cong Sun
Cell & Bioscience.2015;5(1)250
5Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases
Charles J. Malemud
Current Pharmacology Reports.2018;4(5)358
6Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface
Won-Ha Lee,Donggun Seo,Su-Geun Lim,Kyoungho Suk
Frontiers in Immunology.2019;10(5)358
7All-Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice
Michelle H. Theus,Joshua B. Sparks,Xiaofeng Liao,Jingjing Ren,Xin M. Luo
Journal of Histochemistry & Cytochemistry.2017;65(2)69
8Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension
Ronald F van Vollenhoven,Sandra V Navarra,Roger A Levy,Mathew Thomas,Amy Heath,Todd Lustine,Anthony Adamkovic,James Fettiplace,Mei-Lun Wang,Beulah Ji,David Roth
9Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis
Simin Jamaly,Mehrdad Rakaee,Reza Abdi,George C. Tsokos,Kristin Andreassen Fenton
Autoimmunity Reviews.2021;20(12)102980
10Systemic lupus erythematosus today
José Mario Sabio
Medicina Clínica (English Edition).2016;146(4)160
11Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial
Yoshiya Tanaka,Damon Bass,Myron Chu,Sally Egginton,Beulah Ji,David Roth
Modern Rheumatology.2020;30(2)313
12Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus
Leong Tung Ong,Nicholas Ming Zher Chee
Current Treatment Options in Rheumatology.2021;7(3)272
13To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies
Annalisa Marcuzzi,Elisa Piscianz,Erica Valencic,Lorenzo Monasta,Liza Brumatti,Alberto Tommasini
International Journal of Molecular Sciences.2015;16(9)21277
14Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Veena A. Thomas,Joseph P. Balthasar
15Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina
A Babini,A M Cappuccio,C Caprarulo,G Casado,A Eimon,H Figueredo,M A García,S Magri,P Mannucci,S Perez Rodriguez,B A Pons-Estel,E J Velozo,M Iglesias-Rodriguez,G Streger
16Lupus nephritis and B-cell targeting therapy
Matthias Cassia,Federico Alberici,Maurizio Gallieni,David Jayne
Expert Review of Clinical Immunology.2017;13(10)951
17Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus
M Prete,P Leone,M A Frassanito,V Desantis,C Marasco,S Cicco,F Dammacco,A Vacca,V Racanelli
18Belimumab in the management of systemic lupus erythematosus – an update
Vladimir Tesar,Zdenka Hruskova
Expert Opinion on Biological Therapy.2017;17(7)901
19Myasthenia Gravis – A Review of Current Therapeutic Options
Saiju Jacob
European Neurological Review.2018;13(2)86
20Discovery and Qualification of Candidate Urinary Biomarkers of Disease Activity in Lupus Nephritis
Veronica G. Anania,Kebing Yu,Francesco Pingitore,Qingling Li,Christopher M. Rose,Peter Liu,Wendy Sandoval,Ann E. Herman,Jennie R. Lill,W. Rodney Mathews
Journal of Proteome Research.2019;18(3)1264
21Lupus eritematoso sistémico a día de hoy
José Mario Sabio
Medicina Clínica.2016;146(4)160
22Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases
Salar Pashangzadeh,Morteza Motallebnezhad,Fatemeh Vafashoar,Azadeh Khalvandi,Nazanin Mojtabavi
Frontiers in Immunology.2021;12(4)160
23Systemic lupus erythematosus and atherosclerosis: Review of the literature
Marianne Frieri,Heather Stampfl
Autoimmunity Reviews.2016;15(1)16